Parse Biosciences and Graph Therapeutics announced a strategic collaboration to generate a large‑scale immune cell perturbation atlas. Parse will apply its GigaLab single‑cell whole‑transcriptome sequencing platform while Graph uses lab‑in‑the‑loop systems to produce patient‑derived disease models. The partners plan to profile hundreds of millions of cells under systematic perturbations to map immune and tissue interactions relevant to immune‑related disorders. Parse was recently acquired by Qiagen, positioning its single‑cell capabilities within a larger life‑science tools portfolio. The atlas aims to serve as a discovery infrastructure to de‑risk target identification and to streamline preclinical validation for immune therapeutics.